24 Oct 2008
Herceptin Decision Criticised
National's decision to fund 12 months of the breast cancer drug herceptin is criticised as undermining Pharmac's independence.
Recent stories from Morning Report
Get the RNZ app
for easy access to all your favourite programmes
